ES2339333T5 - Anticuerpos anti-CD30 recombinantes y usos de los mismos - Google Patents

Anticuerpos anti-CD30 recombinantes y usos de los mismos Download PDF

Info

Publication number
ES2339333T5
ES2339333T5 ES01986050T ES01986050T ES2339333T5 ES 2339333 T5 ES2339333 T5 ES 2339333T5 ES 01986050 T ES01986050 T ES 01986050T ES 01986050 T ES01986050 T ES 01986050T ES 2339333 T5 ES2339333 T5 ES 2339333T5
Authority
ES
Spain
Prior art keywords
antibody
seq
cells
disease
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01986050T
Other languages
English (en)
Spanish (es)
Other versions
ES2339333T3 (es
Inventor
Joseph A. Francisco
Grant Risdon
Alan F. Wahl
Clay B. Siegall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24910311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2339333(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Application granted granted Critical
Publication of ES2339333T3 publication Critical patent/ES2339333T3/es
Publication of ES2339333T5 publication Critical patent/ES2339333T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES01986050T 2000-11-28 2001-11-28 Anticuerpos anti-CD30 recombinantes y usos de los mismos Expired - Lifetime ES2339333T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US724406 2000-11-28
US09/724,406 US7090843B1 (en) 2000-11-28 2000-11-28 Recombinant anti-CD30 antibodies and uses thereof
PCT/US2001/044811 WO2002043661A2 (en) 2000-11-28 2001-11-28 Recombinant anti-cd30 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
ES2339333T3 ES2339333T3 (es) 2010-05-19
ES2339333T5 true ES2339333T5 (es) 2013-09-26

Family

ID=24910311

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01986050T Expired - Lifetime ES2339333T5 (es) 2000-11-28 2001-11-28 Anticuerpos anti-CD30 recombinantes y usos de los mismos

Country Status (12)

Country Link
US (1) US7090843B1 (https=)
EP (1) EP1347730B2 (https=)
JP (1) JP4303964B2 (https=)
AT (1) ATE454124T1 (https=)
AU (2) AU2002236518B2 (https=)
CA (1) CA2430135C (https=)
CY (1) CY1110700T1 (https=)
DE (1) DE60141043D1 (https=)
DK (1) DK1347730T4 (https=)
ES (1) ES2339333T5 (https=)
PT (1) PT1347730E (https=)
WO (1) WO2002043661A2 (https=)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
CA2467242A1 (en) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
CA2471645A1 (en) * 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
IL162835A0 (en) * 2002-01-09 2005-11-20 Medarex Inc Human monoclonal antibodies against cd30
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
DK1545613T3 (da) * 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
WO2006039644A2 (en) 2004-10-01 2006-04-13 Medarex, Inc. Methods of treating cd30 positive lymphomas
ES2498794T3 (es) 2005-02-18 2014-09-25 Medarex, L.L.C. Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo
WO2007044616A2 (en) 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
US8257706B2 (en) * 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
EP2176295B1 (en) 2007-07-16 2014-11-19 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
PE20090943A1 (es) 2007-07-16 2009-08-05 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
EA020696B1 (ru) * 2007-10-12 2015-01-30 Сиэтл Дженетикс, Инк. Способ лечения лимфомы ходжкина с использованием комбинации гемцитабина и конъюгата антитела против cd30 с ауристатином
KR101607346B1 (ko) 2008-01-31 2016-03-29 제넨테크, 인크. 항-cd79b 항체 및 면역접합체 및 사용 방법
EP2326350B1 (en) 2008-09-08 2013-09-04 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
WO2010081004A1 (en) 2009-01-09 2010-07-15 Seattle Genetics, Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
EP3581206B8 (en) 2010-10-22 2025-02-19 Seagen Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
EP2793947B1 (en) 2011-12-23 2021-02-03 Innate Pharma Enzymatic conjugation of polypeptides
US9926373B2 (en) * 2012-04-27 2018-03-27 Novo Nordisk A/S Human CD30 ligand antigen binding proteins
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体-薬物コンジュゲート
EP3564259A3 (en) 2012-11-09 2020-02-12 Innate Pharma Recognition tags for tgase-mediated conjugation
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
US9089614B2 (en) 2012-12-21 2015-07-28 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
MX2015012549A (es) 2013-03-15 2016-06-21 Abbvie Deutschland Formulaciones de conjugado anticuerpo anti-egfr-farmaco.
EP2968589A1 (en) 2013-03-15 2016-01-20 AbbVie Inc. Antibody drug conjugate (adc) purification
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
CA2908380A1 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
CN105517577A (zh) 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
US10562977B2 (en) 2014-01-29 2020-02-18 Shanghai Hengrui Pharmaceutical Co., Ltd. Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
HUE049175T2 (hu) 2014-09-23 2020-09-28 Hoffmann La Roche Eljárás anti-CD79b immunkonjugátumok alkalmazására
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
TW201717935A (zh) 2015-06-03 2017-06-01 波士頓生醫公司 用於治療癌症的組成物和方法
CA2989269C (en) 2015-06-15 2020-09-22 Robert Yongxin Zhao Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
FI3380620T3 (fi) 2015-11-23 2024-08-01 Novartis Ag Optimoituja lentiviruksen siirtovektoreita ja niiden käyttötapoja
RU2018127657A (ru) 2015-12-30 2020-01-31 Новартис Аг Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью
IL260289B (en) 2016-01-08 2022-08-01 Bioalliance Cv Tetravalent anti-psgl-1 antibodies and uses thereof
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
CN109843919A (zh) 2016-03-25 2019-06-04 西雅图基因公司 用于制备聚乙二醇化的药物-接头及其中间体的方法
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
KR20220150408A (ko) 2016-11-14 2022-11-10 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
CN110022938A (zh) 2016-11-14 2019-07-16 千禧制药公司 抗cd30抗体药物缀合物的非成年人给药
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
CN106854245A (zh) * 2016-12-28 2017-06-16 无锡傲锐东源生物科技有限公司 抗cd30蛋白单克隆抗体及其用途
ES2912408T3 (es) 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
CN110582509A (zh) 2017-01-31 2019-12-17 诺华股份有限公司 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
WO2018158716A1 (en) 2017-03-02 2018-09-07 Cadila Healthcare Limited Novel protein drug conjugate formulation
KR102648564B1 (ko) 2017-03-24 2024-03-19 씨젠 인크. 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US11795229B2 (en) 2017-10-11 2023-10-24 Seattle Genetics, Inc. Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
RU2020116579A (ru) 2017-10-25 2021-11-25 Новартис Аг Способы получения клеток, экспрессирующих химерный антигенный рецептор
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
US20220226439A1 (en) 2017-11-01 2022-07-21 Seagen Inc. Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
CN117126279A (zh) 2018-03-20 2023-11-28 鸿运华宁(杭州)生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
TW202003047A (zh) 2018-03-23 2020-01-16 美商西雅圖遺傳學公司 包括微管蛋白破壞劑之抗體藥物結合物治療實體腫瘤之用途
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3856777A1 (en) 2018-09-24 2021-08-04 The Medical College of Wisconsin, Inc. Anti-cd30 antibodies and methods of use
WO2020063676A1 (zh) 2018-09-26 2020-04-02 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
US20200102399A1 (en) 2018-10-01 2020-04-02 Seattle Genetics, Inc. Methods of Treating Peripheral T Cell Lymphoma Using Anti-CD30 Antibody Drug Conjugate Therapy
JP7699542B2 (ja) 2018-11-20 2025-06-27 コーネル ユニバーシティー 放射線核種の大環状錯体およびがんの放射線療法におけるそれらの使用
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
WO2020210719A1 (en) 2019-04-10 2020-10-15 Elevatebio Management, Inc. Flt3-specific chimeric antigen receptors and methods of using the same
CN112125915A (zh) 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
AU2020351751A1 (en) 2019-09-25 2022-04-21 Seagen Inc. Combination anti-CD30 ADC, anti-PD-1 and chemotherapeutic for treatment of hematopoietic cancers
CN114929284A (zh) 2019-10-04 2022-08-19 西根公司 喜树碱肽缀合物
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
WO2021091815A1 (en) 2019-11-04 2021-05-14 Seagen Inc. Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
BR112022011902A2 (pt) 2019-12-20 2022-09-06 Novartis Ag Terapias de combinação
JP7821733B2 (ja) 2020-01-22 2026-02-27 上海森輝医薬有限公司 エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
EP4096713A1 (en) 2020-01-31 2022-12-07 Seagen Inc. Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
CN115103858B (zh) 2020-03-25 2025-07-15 江苏恒瑞医药股份有限公司 一种抗体药物偶联物的制备方法
BR112022019073A2 (pt) 2020-03-25 2022-11-08 Jiangsu Hengrui Pharmaceuticals Co Ltd Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma
AU2021251875A1 (en) 2020-04-10 2022-11-03 Seagen Inc. Charge variant linkers
CA3183602A1 (en) 2020-05-13 2021-11-18 Seagen Inc. Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
JP2023529211A (ja) 2020-06-11 2023-07-07 ノバルティス アーゲー Zbtb32阻害剤及びその使用
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
JP2024503508A (ja) 2021-01-15 2024-01-25 シージェン インコーポレイテッド 免疫調節性抗体-薬物コンジュゲート
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
CN117597150A (zh) 2021-04-20 2024-02-23 思进公司 抗体依赖性细胞毒性的调节
WO2022229853A1 (en) 2021-04-27 2022-11-03 Novartis Ag Viral vector production system
AU2022283467A1 (en) 2021-05-28 2023-12-07 Seagen Inc. Anthracycline antibody conjugates
MX2024005080A (es) 2021-10-29 2024-05-13 Seagen Inc Metodos para tratar cancer con una combinacion de un anticuerpo anti-pd-1 y un conjugado de anticuerpo anti-cd30-farmaco.
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
CN114891101B (zh) * 2021-12-02 2023-06-16 吉林省农业科学院 一种牛肌肉生长抑制素蛋白单克隆抗体及其应用
WO2023178289A2 (en) 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
EP4518905A1 (en) 2022-05-06 2025-03-12 Seagen Inc. Immunomodulatory antibody-drug conjugates
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
CN121311250A (zh) 2023-03-22 2026-01-09 信立泰生物医药公司 抗5t4抗原结合结构域、抗体-药物缀合物及其使用方法
PE20252789A1 (es) 2023-05-24 2025-12-22 Kumquat Biosciences Inc Compuestos heterociclicos y usos de estos
AR134171A1 (es) 2023-10-24 2025-12-10 Seagen Inc Compuestos quimioterapéuticos y métodos de uso
WO2025096626A1 (en) 2023-10-31 2025-05-08 Seagen Inc. Methods of treating cancers using anti-cd30 antibody-drug conjugates
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
WO2025169056A1 (en) 2024-02-06 2025-08-14 Seagen Inc. Methods of treating cancers using anti-cd30 antibody-drug conjugates
CN119331093B (zh) * 2024-11-04 2025-07-11 武汉伊莱瑞特生物科技股份有限公司 一种抗CD30的兔源Fab抗体及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6909191A (en) 1989-11-20 1991-06-13 Parker, David L. Improved cd-30 antibodies and fragments thereof
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
DE4200043A1 (de) 1991-11-11 1993-05-13 Stein Harald Prof Dr Lymphoides cd30-antigen (ki-1), dessen protein- und die zugehoerige nucleotidsequenz, seine herstellung sowie mittel zur diagnose und untersuchung von tumoren
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
ATE311895T1 (de) 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
ES2157225T3 (es) 1992-10-09 2001-08-16 Advanced Tissue Sciences Inc Celulas hepaticas de reserva.
CA2153165C (en) 1993-01-14 2003-05-06 Hiroaki Maeda Recombinant anti-hiv antibody and process for preparing the same
DE69534530T2 (de) * 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
ATE186745T1 (de) 1995-01-18 1999-12-15 Roche Diagnostics Gmbh Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern
DE19543039C1 (de) 1995-11-08 1996-11-21 Medac Klinische Spezialpraep Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30
DE19640733A1 (de) * 1996-10-02 1998-04-09 Abken Hinrich Verfahren zur Hemmung der unbegrenzten Profileration, Tumorbildung oder Metastasierung CD30 Antigen exprimierender Zellen
ATE372130T1 (de) 2000-04-22 2007-09-15 Pharmedartis Gmbh Apoptotika
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
CA2467242A1 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies

Also Published As

Publication number Publication date
ATE454124T1 (de) 2010-01-15
DE60141043D1 (de) 2010-02-25
DK1347730T4 (da) 2020-04-27
JP4303964B2 (ja) 2009-07-29
EP1347730B1 (en) 2010-01-06
PT1347730E (pt) 2010-03-03
WO2002043661A3 (en) 2003-01-16
EP1347730A2 (en) 2003-10-01
CY1110700T1 (el) 2015-06-10
CA2430135A1 (en) 2002-06-06
EP1347730B2 (en) 2013-05-29
WO2002043661A2 (en) 2002-06-06
JP2005506035A (ja) 2005-03-03
AU2002236518B2 (en) 2006-10-26
ES2339333T3 (es) 2010-05-19
WO2002043661B1 (en) 2003-03-06
US7090843B1 (en) 2006-08-15
CA2430135C (en) 2012-10-02
EP1347730A4 (en) 2005-08-17
DK1347730T3 (da) 2010-02-01
AU3651802A (en) 2002-06-11

Similar Documents

Publication Publication Date Title
ES2339333T5 (es) Anticuerpos anti-CD30 recombinantes y usos de los mismos
US12234281B2 (en) Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
US10858444B2 (en) T cell receptor-like antibodies specific for a WTI peptide presented by HLA-A2
AU2002236518A1 (en) Recombinant anti-CD30 antibodies and uses thereof
JP2021531826A (ja) 栄養膜細胞表面抗原2(trop2)に対する特異的な抗体
JP2021525080A (ja) GUCY2cに特異的な抗体及びその使用
JP7623939B2 (ja) 葉酸受容体アルファに特異的な抗体
US20230293687A1 (en) T cells and chimeric stimulating receptors and uses thereof
TW202043275A (zh) Cd44特異性抗體
ES2825625T3 (es) Anticuerpos anti-CD38 específicos para tratar cánceres humanos
KR20230116007A (ko) 항-cd30 항체-약물 접합체를 사용한 면역 반응 조절
CA2735433C (en) Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
US20220169746A1 (en) Antibodies to neoantigens and uses thereof
WO2025162471A1 (en) Antibodies and antibody-drug conjugates targeting ox40 and uses thereof
AU2007200173B2 (en) Recombinant anti-CD30 antibodies and uses thereof
BR112020001320A2 (pt) combinações farmacêuticas que compreendem um anticorpo anti-bst-1 e um análogo de citidina
KR20230107478A (ko) 치료 항체 및 그의 용도
HK40105152A (zh) 对muc18特异性的抗体
TW202430210A (zh) 用於治療癌症之btn3a活化抗體、bcl2抑制劑及去甲基化劑之組合
KR20220088438A (ko) 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
HK40060753B (zh) 对muc18特异性的抗体
HK40060091A (en) Antibodies specific for gucy2c and uses thereof
HK1255960B (en) T cell receptor-like bispecific antibodies specific for a wt1 peptide presented by hla-a2
HK1255960A1 (en) T cell receptor-like bispecific antibodies specific for a wt1 peptide presented by hla-a2
HK40008679A (en) Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof